MA50806A - Azacycles substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 - Google Patents
Azacycles substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1Info
- Publication number
- MA50806A MA50806A MA050806A MA50806A MA50806A MA 50806 A MA50806 A MA 50806A MA 050806 A MA050806 A MA 050806A MA 50806 A MA50806 A MA 50806A MA 50806 A MA50806 A MA 50806A
- Authority
- MA
- Morocco
- Prior art keywords
- muscarinic
- receptor
- positive allosteric
- allosteric modulators
- substituted azacycles
- Prior art date
Links
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 title 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741042082 | 2017-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50806A true MA50806A (fr) | 2020-09-30 |
Family
ID=64744766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050806A MA50806A (fr) | 2017-11-23 | 2018-11-21 | Azacycles substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12156871B2 (fr) |
| EP (1) | EP3713940B1 (fr) |
| JP (1) | JP7034284B2 (fr) |
| KR (1) | KR102443402B1 (fr) |
| CN (1) | CN111386270B (fr) |
| AU (1) | AU2018372664B2 (fr) |
| BR (1) | BR112020010138A2 (fr) |
| CA (1) | CA3082724C (fr) |
| DK (1) | DK3713940T3 (fr) |
| EA (1) | EA039902B1 (fr) |
| HR (1) | HRP20220736T1 (fr) |
| HU (1) | HUE058954T2 (fr) |
| IL (1) | IL274708B (fr) |
| MA (1) | MA50806A (fr) |
| MX (1) | MX2020005341A (fr) |
| NZ (1) | NZ764561A (fr) |
| SG (1) | SG11202004580WA (fr) |
| WO (1) | WO2019102365A1 (fr) |
| ZA (1) | ZA202002938B (fr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012003147A1 (fr) * | 2010-07-01 | 2012-01-05 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 de l'isoindolone |
| EP2709451B1 (fr) | 2011-05-17 | 2015-12-30 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 contenant des lactames liés à n |
| WO2013063549A1 (fr) | 2011-10-28 | 2013-05-02 | Vanderbilt University | Analogues substitues 2-(4-heterocyclylbenzyle)isoindoline-1-un employes comme modulateurs allosteriques positifs du recepteur m1 acetylcholine muscarinique |
| MX373274B (es) * | 2014-04-23 | 2020-04-16 | Takeda Pharmaceuticals Co | Derivados de isoindolin-1-ona con actividad de modulador alostérico positivo del receptor colinérgico muscarínico m1 para el tratamiento de la enfermedad de alzheimer. |
| ES2789756T3 (es) * | 2015-12-23 | 2020-10-26 | Merck Sharp & Dohme | Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4 |
| WO2018005249A1 (fr) | 2016-06-28 | 2018-01-04 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 de benzoisoquinoline |
-
2018
- 2018-11-21 CA CA3082724A patent/CA3082724C/fr active Active
- 2018-11-21 DK DK18822142.8T patent/DK3713940T3/da active
- 2018-11-21 CN CN201880075861.2A patent/CN111386270B/zh active Active
- 2018-11-21 HU HUE18822142A patent/HUE058954T2/hu unknown
- 2018-11-21 NZ NZ764561A patent/NZ764561A/en unknown
- 2018-11-21 MX MX2020005341A patent/MX2020005341A/es unknown
- 2018-11-21 US US16/766,112 patent/US12156871B2/en active Active
- 2018-11-21 SG SG11202004580WA patent/SG11202004580WA/en unknown
- 2018-11-21 EA EA202091302A patent/EA039902B1/ru unknown
- 2018-11-21 JP JP2020528300A patent/JP7034284B2/ja active Active
- 2018-11-21 BR BR112020010138-9A patent/BR112020010138A2/pt unknown
- 2018-11-21 MA MA050806A patent/MA50806A/fr unknown
- 2018-11-21 KR KR1020207017949A patent/KR102443402B1/ko active Active
- 2018-11-21 AU AU2018372664A patent/AU2018372664B2/en active Active
- 2018-11-21 EP EP18822142.8A patent/EP3713940B1/fr active Active
- 2018-11-21 HR HRP20220736TT patent/HRP20220736T1/hr unknown
- 2018-11-21 WO PCT/IB2018/059164 patent/WO2019102365A1/fr not_active Ceased
-
2020
- 2020-05-17 IL IL274708A patent/IL274708B/en unknown
- 2020-05-20 ZA ZA2020/02938A patent/ZA202002938B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3713940T3 (da) | 2022-06-20 |
| HRP20220736T1 (hr) | 2022-09-02 |
| EA039902B1 (ru) | 2022-03-25 |
| IL274708B (en) | 2022-06-01 |
| AU2018372664B2 (en) | 2020-11-19 |
| JP2021504357A (ja) | 2021-02-15 |
| ZA202002938B (en) | 2021-04-28 |
| WO2019102365A1 (fr) | 2019-05-31 |
| SG11202004580WA (en) | 2020-06-29 |
| KR20200090854A (ko) | 2020-07-29 |
| CA3082724A1 (fr) | 2019-05-31 |
| HUE058954T2 (hu) | 2022-10-28 |
| CN111386270B (zh) | 2022-05-03 |
| CA3082724C (fr) | 2022-05-31 |
| AU2018372664A1 (en) | 2020-06-04 |
| MX2020005341A (es) | 2020-08-13 |
| BR112020010138A2 (pt) | 2020-11-10 |
| KR102443402B1 (ko) | 2022-09-15 |
| US20210369685A1 (en) | 2021-12-02 |
| CN111386270A (zh) | 2020-07-07 |
| NZ764561A (en) | 2021-12-24 |
| EP3713940A1 (fr) | 2020-09-30 |
| EA202091302A1 (ru) | 2020-08-17 |
| US12156871B2 (en) | 2024-12-03 |
| IL274708A (en) | 2020-07-30 |
| EP3713940B1 (fr) | 2022-05-04 |
| JP7034284B2 (ja) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44253A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 | |
| HUE053586T2 (hu) | Muszkarin M1 receptor pozitív alloszterikus modulátorok | |
| LT3864003T (lt) | Integruoto streso mechanizmo provaistų moduliatoriai | |
| MA45463A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| EP3347372A4 (fr) | Macrocycles peptidomimétiques en tant que modulateurs de mcl-1 | |
| DK3452448T3 (da) | Modulatorer af den integrerede stressvej | |
| EP3356356A4 (fr) | Composés utiles en tant que modulateurs de trpm8 | |
| EP3509588A4 (fr) | Composés bicycliques utiles en tant que modulateurs du gpr120 | |
| EP3558946A4 (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| MA46722A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
| MA44772A (fr) | 6-aminopyridine-3-yl thiazoles utilisés en tant que modulateurs de ror t | |
| EP3544961A4 (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| MA50464A (fr) | Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA47126A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
| MA52286A (fr) | Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine | |
| HUE063823T2 (hu) | Heterociklusos vegyület és annak alkalmazása a kolinerg muszkarin M1 receptor pozitív alloszterikus modulátoraként | |
| MA46461A (fr) | Sulfones tricycliques en tant que modulateurs de ror gamma | |
| IL257869A (en) | Fluoroindole derivatives as positive allosteric modulators for muscarinic receptor am.1 | |
| MA50402A (fr) | Composés hétéroaryle utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA51036A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| MA50806A (fr) | Azacycles substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA51037A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
| MA53917A (fr) | Dérivés de pyrrolo-pyridazine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique | |
| EP3621951A4 (fr) | Diarylurées en tant que modulateurs allostériques de cb1 | |
| HK40002190A (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |